Shots:

• The company has enrolled the 1st patient in a P-IIb trial to evaluate HZN-825 (300mg, qd/bid) in a ratio (1:1:1) in 300 patients with dcSSc for 52wks. The study is based on the results of a P-IIa trial
• The 1EPs of the study is the change in FVC% after 52wks. of treatment & 2EPs include HAQ-DI, and other patient and physician-reported outcome measures for efficacy assessment. Additionally, patients will be eligible to enter in a 52wks. extension trial after completing the 52wks. treatment
• HZN-825 (PO) is a selective LPAR1 antagonist that showed early signs of clinical impact in systemic sclerosis

  Ref: Horizon | Image: Horizon